Development and initial validation of the MS score for diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis
- PMID: 31296501
- DOI: 10.1136/annrheumdis-2019-215211
Development and initial validation of the MS score for diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis
Abstract
Objective: To develop and validate a diagnostic score that aids in identifying macrophage activation syndrome (MAS) in patients with systemic juvenile idiopathic arthritis (sJIA).
Methods: The clinical and laboratory features of 362 patients with sJIA-associated MAS and 404 patients with active sJIA without evidence of MAS were collected in a multinational collaborative project. Eighty percent of the study population was used to develop the score and the remaining 20% constituted the validation sample. A Bayesian Model Averaging approach was used to assess the role of each clinical and laboratory variables in the diagnosis of MAS and to obtain the coefficients of selected variables. The final score, named MAS/sJIA (MS) score, resulted from the linear combination of these coefficients multiplied by the values of each variable. The cut-off that best discriminated MAS from active sJIA was calculated by means of receiver operating characteristic (ROC) curve analysis. Score performance was evaluated in both developmental and validation samples.
Results: The MS score ranges from -8.4 to 41.8 and comprises seven variables: central nervous system dysfunction, haemorrhagic manifestations, active arthritis, platelet count, fibrinogen, lactate dehydrogenase and ferritin. A cut-off value ≥-2.1 revealed the best performance in discriminating MAS from active sJIA, with a sensitivity of 0.85, a specificity of 0.95 and a kappa value of 0.80. The good performance of the MS score was confirmed in the validation sample.
Conclusion: The MS score is a powerful and feasible tool that may assist practitioners in making a timely diagnosis of MAS in patients with sJIA.
Keywords: diagnostic score; hemophagocytic syndrome; macrophage activation syndrome; still’s disease; systemic juvenile idiopathic arthritis.
© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.
Conflict of interest statement
Competing interests: None declared.
Comment in
-
MS score in systemic juvenile idiopathic arthritis: suitable for routine use?Ann Rheum Dis. 2021 Jul;80(7):e107. doi: 10.1136/annrheumdis-2019-216041. Epub 2019 Aug 2. Ann Rheum Dis. 2021. PMID: 31375525 No abstract available.
-
Response to: 'MS score in systemic juvenile idiopathic arthritis: suitable for routine use?' by Chi et al.Ann Rheum Dis. 2021 Jul;80(7):e108. doi: 10.1136/annrheumdis-2019-216067. Epub 2019 Aug 16. Ann Rheum Dis. 2021. PMID: 31420325 No abstract available.
-
Application of MS score in macrophage activation syndrome patients associated with adult onset Still's disease.Ann Rheum Dis. 2021 Sep;80(9):e145. doi: 10.1136/annrheumdis-2019-216286. Epub 2019 Oct 14. Ann Rheum Dis. 2021. PMID: 31611222 No abstract available.
-
Response to 'Application of MS score in macrophage activation syndrome patients associated with adult onset Still's disease' by Wang et al.Ann Rheum Dis. 2021 Sep;80(9):e146. doi: 10.1136/annrheumdis-2019-216310. Epub 2019 Oct 25. Ann Rheum Dis. 2021. PMID: 31653650 No abstract available.
-
Comparison of MS score and HScore for the diagnosis of adult-onset Still's disease-associated macrophage activation syndrome.Ann Rheum Dis. 2022 Jun;81(6):e99. doi: 10.1136/annrheumdis-2020-217917. Epub 2020 Jul 1. Ann Rheum Dis. 2022. PMID: 32611598 No abstract available.
-
Response to: 'Comparison of MS score and HScore for the diagnosis of adult-onset Still's disease associated macrophage activation syndrome' by Zhang et al.Ann Rheum Dis. 2022 Jun;81(6):e100. doi: 10.1136/annrheumdis-2020-218033. Epub 2020 Jul 1. Ann Rheum Dis. 2022. PMID: 32611601 No abstract available.